The Gleason score is crucial for predicting the aggressiveness of prostate cancer and helps in guiding treatment decisions. A low Gleason score (2-6) suggests a less aggressive cancer with a better prognosis, whereas a high Gleason score (8-10) indicates a more aggressive cancer with a poorer prognosis. Intermediate scores (7) require careful clinical assessment to determine the appropriate management strategy.
